BridgeBio Oncology Therapeutics Inc. (BBOT) vs C4 Therapeutics, Inc. (CCCC)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and C4 Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.63HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
CCCC
C4 Therapeutics, Inc.
$2.91HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
Total return — BBOT vs CCCC
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)CCCC -46.8% (-19.0%/yr)CCCC compounded faster over this window
BBOT CCCC
BBOT vs CCCC: by the numbers
- •CCCC is the larger company ($321M vs $291M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -289.44% net margin).
Metrics side by side
Valuation
| Metric | BBOT | CCCC |
|---|---|---|
| P/S ratio | N/A | 9.17 |
| P/B ratio | 0.90 | 1.30 |
Profitability
| Metric | BBOT | CCCC |
|---|---|---|
| Gross margin | 0.00% | 77.81% |
| Operating margin | 0.00% | -290.68% |
| Net margin | 0.00% | -289.44% |
| ROE | -56.36% | -41.02% |
| ROIC | -61.10% | -35.92% |
Growth (annualized)
| Metric | BBOT | CCCC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 0.65% |
| Total return CAGR (5Y) | N/A | -41.77% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.